|
Great advances have been made in the treatment of many cancers in the last 25 years. Histological and genomic research has led to the identification of prognostic and predictive markers for various tumors and has provided insight into drug response mechanisms. One of the most challenging issues, however, is to understand why patients with histologically similar tumors respond differently to standard drug treatments.
Extensive research has resulted in the development and delivery of ChemoFx®, a test that assists physicians in overcoming this challenge. ChemoFx® is designed to provide predictive information to help physicians choose between chemotherapy drugs, eliminate potentially ineffective drugs from treatment regimens and assist in the formulation of an optimal therapy choice for each patient. This may spare the patient from unnecessary toxicity associated with ineffective treatment and offers a better chance of tumor response resulting in progression-free survival.
ChemoFx® : Unique Benefits
• Specific drug response profile: assists oncologists in the management of the patient's
treatment - an adjunct to the physician's clinical expertise and medical knowledge of
the patient's disease
• Predicts likelihood of tumor response to physician selected chemotherapy agents creating
enhanced clinical insight for treatment decisions
• Small samples are required that are easily collected by core biopsy or during planned
primary surgical investigation
• In vitro-In vivo correlations have been shown in published clinical data
• Prospective ongoing clinical trials continue to improve the predictive accuracy and
increase knowledge
• Scientific advisors and partnerships make significant contributions to research and
clinical trials
• ChemoFx® has been covered by Medicare and over 400 commercial insurance companies
1 Gallion, H. H., W. A. Christopherson, et al. (Jan/Feb 2006). "Relationship between ex vivo chemosensitivity assay and progression free interval in ovarian cancer." International Journal of Gynecological Cancer
|
